TABLE 3.

Causal prophylaxis activity of KAI407 in an in vivo rodent malaria model using P. berghei

Compound	Dosea (mg/kg)	Survival (%)	Prepatent periodb (days ± SD)
Vehicle (untreated)		0	5.75 ± 0.46
Atovaquone	2.5	100	NAd
KAI407c	20	0	6.5 ± 0.53
KAI407c	100	100	NAd

^aA single dose was administered via oral gavage 1–2 h prior to P. berghei sporozoite infection.

^bAverage number of days before blood-stage parasitemia was detected by microscopy.

^cFormulated in 0.5% (wt/vol) methylcellulose, 0.1% (vol/vol) Tween 80.

^dNA, not applicable; 100% prophylaxis achieved.